MADISON — The specter of a drug-resistant form of the deadly H5N1 avian influenza is a nightmare to keep public health officials awake at night. Now, however, a study published this week (Dec. 21) in the Proceedings of the National Academy of Sciences (PNAS) suggests that a new compound, one on the threshold of final testing in humans, may be more potent and safer for treating "bird flu" than the antiviral drug best known by the trade name Tamiflu. Known as T-705, the compound even works several days after infection, according to Yoshihiro Kawaoka, a University of Wisconsin-Madison virologist and...